Key facts
- Signatur Biosciences’s last known valuation is $7.1M (Jan 2022).
- It has raised $7.5M; the latest was Seed Round ($7.0M) in May 2025.
- Notable investors include Y Combinator, Imperial Enterprise Lab, Noshaq, Anjost Investment, PSR Crypto — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Signatur Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Signatur Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Signatur Biosciences
Developer of a PCR testing platform designed to make precision diagnostics accessible to all. The company's technology uses the molecular machinery of PCR to condense all the work of detecting and interpreting a panel of RNA biomarkers into a single test, and offers a smart kit compatible with existing machines and off-the-shelf reagents, enabling clinicians to integrate with existing clinical workflows and infrastructure.
- Sector
- Healthcare
- HQ
- Thame, United Kingdom
- Founded
- 2022
- Employees
- 9
- Website
- signatur.bio/
- Ownership
- Privately Held (backing)
Signatur Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Signatur Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Signatur Biosciences in its N-PORT filings yet. We sweep new filings monthly.